nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—Mouth ulceration—Sorafenib—liver cancer	0.0164	0.0196	CcSEcCtD
Darifenacin—Ulcerative stomatitis—Epirubicin—liver cancer	0.0145	0.0173	CcSEcCtD
Darifenacin—Ulcerative stomatitis—Doxorubicin—liver cancer	0.0134	0.016	CcSEcCtD
Darifenacin—Dry skin—Sorafenib—liver cancer	0.0121	0.0144	CcSEcCtD
Darifenacin—Breast disorder—Sorafenib—liver cancer	0.0119	0.0142	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.0118	0.0141	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Sorafenib—liver cancer	0.0116	0.0139	CcSEcCtD
Darifenacin—Erectile dysfunction—Sorafenib—liver cancer	0.0105	0.0125	CcSEcCtD
Darifenacin—Infestation NOS—Sorafenib—liver cancer	0.0101	0.0121	CcSEcCtD
Darifenacin—Infestation—Sorafenib—liver cancer	0.0101	0.0121	CcSEcCtD
Darifenacin—Stomatitis—Sorafenib—liver cancer	0.00988	0.0118	CcSEcCtD
Darifenacin—Urinary tract disorder—Sorafenib—liver cancer	0.00899	0.0107	CcSEcCtD
Darifenacin—Urethral disorder—Sorafenib—liver cancer	0.00892	0.0107	CcSEcCtD
Darifenacin—Erythema multiforme—Sorafenib—liver cancer	0.00861	0.0103	CcSEcCtD
Darifenacin—Angiopathy—Sorafenib—liver cancer	0.00826	0.00986	CcSEcCtD
Darifenacin—Mediastinal disorder—Sorafenib—liver cancer	0.0082	0.00979	CcSEcCtD
Darifenacin—Mental disorder—Sorafenib—liver cancer	0.00798	0.00952	CcSEcCtD
Darifenacin—Dysgeusia—Sorafenib—liver cancer	0.00776	0.00926	CcSEcCtD
Darifenacin—Cough increased—Epirubicin—liver cancer	0.00732	0.00874	CcSEcCtD
Darifenacin—Thinking abnormal—Epirubicin—liver cancer	0.00732	0.00874	CcSEcCtD
Darifenacin—Angioedema—Sorafenib—liver cancer	0.00724	0.00864	CcSEcCtD
Darifenacin—Syncope—Sorafenib—liver cancer	0.00711	0.00848	CcSEcCtD
Darifenacin—Loss of consciousness—Sorafenib—liver cancer	0.00697	0.00831	CcSEcCtD
Darifenacin—Cough—Sorafenib—liver cancer	0.00692	0.00826	CcSEcCtD
Darifenacin—Hypertension—Sorafenib—liver cancer	0.00684	0.00817	CcSEcCtD
Darifenacin—Thinking abnormal—Doxorubicin—liver cancer	0.00677	0.00808	CcSEcCtD
Darifenacin—Cough increased—Doxorubicin—liver cancer	0.00677	0.00808	CcSEcCtD
Darifenacin—Arthralgia—Sorafenib—liver cancer	0.00675	0.00805	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.0067	0.008	CcSEcCtD
Darifenacin—Vaginal inflammation—Epirubicin—liver cancer	0.0067	0.008	CcSEcCtD
Darifenacin—Dry mouth—Sorafenib—liver cancer	0.0066	0.00788	CcSEcCtD
Darifenacin—Anaphylactic shock—Sorafenib—liver cancer	0.00647	0.00772	CcSEcCtD
Darifenacin—Infection—Sorafenib—liver cancer	0.00643	0.00767	CcSEcCtD
Darifenacin—Shock—Sorafenib—liver cancer	0.00636	0.0076	CcSEcCtD
Darifenacin—Nervous system disorder—Sorafenib—liver cancer	0.00634	0.00757	CcSEcCtD
Darifenacin—Vaginal infection—Epirubicin—liver cancer	0.00632	0.00755	CcSEcCtD
Darifenacin—Skin disorder—Sorafenib—liver cancer	0.00628	0.0075	CcSEcCtD
Darifenacin—Vaginal inflammation—Doxorubicin—liver cancer	0.0062	0.0074	CcSEcCtD
Darifenacin—Dry eye—Epirubicin—liver cancer	0.00619	0.00739	CcSEcCtD
Darifenacin—Bladder pain—Epirubicin—liver cancer	0.00606	0.00723	CcSEcCtD
Darifenacin—Mouth ulceration—Epirubicin—liver cancer	0.00606	0.00723	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00589	0.00703	CcSEcCtD
Darifenacin—Vaginal infection—Doxorubicin—liver cancer	0.00585	0.00699	CcSEcCtD
Darifenacin—Abnormal vision—Epirubicin—liver cancer	0.00584	0.00698	CcSEcCtD
Darifenacin—Mental disability—Epirubicin—liver cancer	0.00581	0.00694	CcSEcCtD
Darifenacin—Dyspnoea—Sorafenib—liver cancer	0.00577	0.00688	CcSEcCtD
Darifenacin—Dry eye—Doxorubicin—liver cancer	0.00573	0.00683	CcSEcCtD
Darifenacin—Dyspepsia—Sorafenib—liver cancer	0.00569	0.0068	CcSEcCtD
Darifenacin—Mouth ulceration—Doxorubicin—liver cancer	0.0056	0.00669	CcSEcCtD
Darifenacin—Bladder pain—Doxorubicin—liver cancer	0.0056	0.00669	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Sorafenib—liver cancer	0.00558	0.00667	CcSEcCtD
Darifenacin—Constipation—Sorafenib—liver cancer	0.00553	0.0066	CcSEcCtD
Darifenacin—Pain—Sorafenib—liver cancer	0.00553	0.0066	CcSEcCtD
Darifenacin—Abnormal vision—Doxorubicin—liver cancer	0.00541	0.00645	CcSEcCtD
Darifenacin—Mental disability—Doxorubicin—liver cancer	0.00538	0.00642	CcSEcCtD
Darifenacin—Gastrointestinal pain—Sorafenib—liver cancer	0.00529	0.00631	CcSEcCtD
Darifenacin—Abdominal pain—Sorafenib—liver cancer	0.00511	0.0061	CcSEcCtD
Darifenacin—Cerebrovascular accident—Epirubicin—liver cancer	0.00496	0.00592	CcSEcCtD
Darifenacin—Hypersensitivity—Sorafenib—liver cancer	0.00477	0.00569	CcSEcCtD
Darifenacin—Face oedema—Epirubicin—liver cancer	0.00469	0.0056	CcSEcCtD
Darifenacin—Asthenia—Sorafenib—liver cancer	0.00464	0.00554	CcSEcCtD
Darifenacin—Cerebrovascular accident—Doxorubicin—liver cancer	0.00459	0.00548	CcSEcCtD
Darifenacin—Pruritus—Sorafenib—liver cancer	0.00458	0.00546	CcSEcCtD
Darifenacin—Dry skin—Epirubicin—liver cancer	0.00446	0.00532	CcSEcCtD
Darifenacin—Diarrhoea—Sorafenib—liver cancer	0.00443	0.00528	CcSEcCtD
Darifenacin—Breast disorder—Epirubicin—liver cancer	0.00439	0.00525	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00438	0.00523	CcSEcCtD
Darifenacin—Face oedema—Doxorubicin—liver cancer	0.00434	0.00519	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00429	0.00512	CcSEcCtD
Darifenacin—Dizziness—Sorafenib—liver cancer	0.00428	0.00511	CcSEcCtD
Darifenacin—Influenza—Epirubicin—liver cancer	0.0042	0.00502	CcSEcCtD
Darifenacin—Dry skin—Doxorubicin—liver cancer	0.00412	0.00492	CcSEcCtD
Darifenacin—Vomiting—Sorafenib—liver cancer	0.00411	0.00491	CcSEcCtD
Darifenacin—Rash—Sorafenib—liver cancer	0.00408	0.00487	CcSEcCtD
Darifenacin—Dermatitis—Sorafenib—liver cancer	0.00407	0.00486	CcSEcCtD
Darifenacin—Breast disorder—Doxorubicin—liver cancer	0.00407	0.00485	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00405	0.00484	CcSEcCtD
Darifenacin—Headache—Sorafenib—liver cancer	0.00405	0.00484	CcSEcCtD
Darifenacin—Bronchitis—Epirubicin—liver cancer	0.00404	0.00483	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00397	0.00474	CcSEcCtD
Darifenacin—Influenza—Doxorubicin—liver cancer	0.00389	0.00464	CcSEcCtD
Darifenacin—Nausea—Sorafenib—liver cancer	0.00384	0.00459	CcSEcCtD
Darifenacin—Weight increased—Epirubicin—liver cancer	0.00383	0.00457	CcSEcCtD
Darifenacin—Infestation—Epirubicin—liver cancer	0.00375	0.00447	CcSEcCtD
Darifenacin—Infestation NOS—Epirubicin—liver cancer	0.00375	0.00447	CcSEcCtD
Darifenacin—Bronchitis—Doxorubicin—liver cancer	0.00374	0.00446	CcSEcCtD
Darifenacin—Stomatitis—Epirubicin—liver cancer	0.00365	0.00436	CcSEcCtD
Darifenacin—Urinary tract infection—Epirubicin—liver cancer	0.00364	0.00435	CcSEcCtD
Darifenacin—Sweating—Epirubicin—liver cancer	0.00359	0.00429	CcSEcCtD
Darifenacin—Weight increased—Doxorubicin—liver cancer	0.00354	0.00423	CcSEcCtD
Darifenacin—Sinusitis—Epirubicin—liver cancer	0.00352	0.0042	CcSEcCtD
Darifenacin—Infestation NOS—Doxorubicin—liver cancer	0.00347	0.00414	CcSEcCtD
Darifenacin—Infestation—Doxorubicin—liver cancer	0.00347	0.00414	CcSEcCtD
Darifenacin—Stomatitis—Doxorubicin—liver cancer	0.00338	0.00404	CcSEcCtD
Darifenacin—Rhinitis—Epirubicin—liver cancer	0.00337	0.00403	CcSEcCtD
Darifenacin—Urinary tract infection—Doxorubicin—liver cancer	0.00337	0.00402	CcSEcCtD
Darifenacin—Pharyngitis—Epirubicin—liver cancer	0.00334	0.00399	CcSEcCtD
Darifenacin—Sweating—Doxorubicin—liver cancer	0.00332	0.00397	CcSEcCtD
Darifenacin—Urinary tract disorder—Epirubicin—liver cancer	0.00332	0.00397	CcSEcCtD
Darifenacin—Oedema peripheral—Epirubicin—liver cancer	0.00331	0.00396	CcSEcCtD
Darifenacin—Urethral disorder—Epirubicin—liver cancer	0.0033	0.00394	CcSEcCtD
Darifenacin—Sinusitis—Doxorubicin—liver cancer	0.00325	0.00388	CcSEcCtD
Darifenacin—Visual impairment—Epirubicin—liver cancer	0.00324	0.00387	CcSEcCtD
Darifenacin—Erythema multiforme—Epirubicin—liver cancer	0.00318	0.0038	CcSEcCtD
Darifenacin—Eye disorder—Epirubicin—liver cancer	0.00314	0.00375	CcSEcCtD
Darifenacin—Rhinitis—Doxorubicin—liver cancer	0.00312	0.00373	CcSEcCtD
Darifenacin—Pharyngitis—Doxorubicin—liver cancer	0.00309	0.00369	CcSEcCtD
Darifenacin—Urinary tract disorder—Doxorubicin—liver cancer	0.00307	0.00367	CcSEcCtD
Darifenacin—Oedema peripheral—Doxorubicin—liver cancer	0.00307	0.00366	CcSEcCtD
Darifenacin—Angiopathy—Epirubicin—liver cancer	0.00305	0.00364	CcSEcCtD
Darifenacin—Urethral disorder—Doxorubicin—liver cancer	0.00305	0.00364	CcSEcCtD
Darifenacin—Mediastinal disorder—Epirubicin—liver cancer	0.00303	0.00362	CcSEcCtD
Darifenacin—Visual impairment—Doxorubicin—liver cancer	0.003	0.00358	CcSEcCtD
Darifenacin—Mental disorder—Epirubicin—liver cancer	0.00295	0.00352	CcSEcCtD
Darifenacin—Erythema multiforme—Doxorubicin—liver cancer	0.00294	0.00351	CcSEcCtD
Darifenacin—Eye disorder—Doxorubicin—liver cancer	0.00291	0.00347	CcSEcCtD
Darifenacin—Flatulence—Epirubicin—liver cancer	0.00289	0.00345	CcSEcCtD
Darifenacin—Dysgeusia—Epirubicin—liver cancer	0.00287	0.00342	CcSEcCtD
Darifenacin—Back pain—Epirubicin—liver cancer	0.00283	0.00338	CcSEcCtD
Darifenacin—Angiopathy—Doxorubicin—liver cancer	0.00282	0.00337	CcSEcCtD
Darifenacin—Mediastinal disorder—Doxorubicin—liver cancer	0.00281	0.00335	CcSEcCtD
Darifenacin—Vision blurred—Epirubicin—liver cancer	0.00276	0.00329	CcSEcCtD
Darifenacin—Mental disorder—Doxorubicin—liver cancer	0.00273	0.00326	CcSEcCtD
Darifenacin—Flatulence—Doxorubicin—liver cancer	0.00267	0.00319	CcSEcCtD
Darifenacin—Dysgeusia—Doxorubicin—liver cancer	0.00265	0.00317	CcSEcCtD
Darifenacin—Syncope—Epirubicin—liver cancer	0.00263	0.00314	CcSEcCtD
Darifenacin—Back pain—Doxorubicin—liver cancer	0.00262	0.00313	CcSEcCtD
Darifenacin—Palpitations—Epirubicin—liver cancer	0.00259	0.00309	CcSEcCtD
Darifenacin—Loss of consciousness—Epirubicin—liver cancer	0.00257	0.00307	CcSEcCtD
Darifenacin—Cough—Epirubicin—liver cancer	0.00256	0.00305	CcSEcCtD
Darifenacin—Vision blurred—Doxorubicin—liver cancer	0.00255	0.00305	CcSEcCtD
Darifenacin—Hypertension—Epirubicin—liver cancer	0.00253	0.00302	CcSEcCtD
Darifenacin—Arthralgia—Epirubicin—liver cancer	0.00249	0.00298	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00248	0.00296	CcSEcCtD
Darifenacin—Dry mouth—Epirubicin—liver cancer	0.00244	0.00291	CcSEcCtD
Darifenacin—Syncope—Doxorubicin—liver cancer	0.00243	0.0029	CcSEcCtD
Darifenacin—Confusional state—Epirubicin—liver cancer	0.00241	0.00288	CcSEcCtD
Darifenacin—Palpitations—Doxorubicin—liver cancer	0.00239	0.00286	CcSEcCtD
Darifenacin—Anaphylactic shock—Epirubicin—liver cancer	0.00239	0.00285	CcSEcCtD
Darifenacin—Oedema—Epirubicin—liver cancer	0.00239	0.00285	CcSEcCtD
Darifenacin—Loss of consciousness—Doxorubicin—liver cancer	0.00238	0.00284	CcSEcCtD
Darifenacin—Infection—Epirubicin—liver cancer	0.00237	0.00283	CcSEcCtD
Darifenacin—Cough—Doxorubicin—liver cancer	0.00236	0.00282	CcSEcCtD
Darifenacin—Shock—Epirubicin—liver cancer	0.00235	0.00281	CcSEcCtD
Darifenacin—Nervous system disorder—Epirubicin—liver cancer	0.00234	0.0028	CcSEcCtD
Darifenacin—Hypertension—Doxorubicin—liver cancer	0.00234	0.00279	CcSEcCtD
Darifenacin—Tachycardia—Epirubicin—liver cancer	0.00233	0.00278	CcSEcCtD
Darifenacin—Skin disorder—Epirubicin—liver cancer	0.00232	0.00277	CcSEcCtD
Darifenacin—Hyperhidrosis—Epirubicin—liver cancer	0.00231	0.00276	CcSEcCtD
Darifenacin—Arthralgia—Doxorubicin—liver cancer	0.00231	0.00275	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00229	0.00274	CcSEcCtD
Darifenacin—Dry mouth—Doxorubicin—liver cancer	0.00226	0.00269	CcSEcCtD
Darifenacin—Confusional state—Doxorubicin—liver cancer	0.00223	0.00266	CcSEcCtD
Darifenacin—Oedema—Doxorubicin—liver cancer	0.00221	0.00264	CcSEcCtD
Darifenacin—Anaphylactic shock—Doxorubicin—liver cancer	0.00221	0.00264	CcSEcCtD
Darifenacin—Infection—Doxorubicin—liver cancer	0.0022	0.00262	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00218	0.0026	CcSEcCtD
Darifenacin—Shock—Doxorubicin—liver cancer	0.00218	0.0026	CcSEcCtD
Darifenacin—Nervous system disorder—Doxorubicin—liver cancer	0.00217	0.00259	CcSEcCtD
Darifenacin—Insomnia—Epirubicin—liver cancer	0.00216	0.00258	CcSEcCtD
Darifenacin—Tachycardia—Doxorubicin—liver cancer	0.00216	0.00258	CcSEcCtD
Darifenacin—Skin disorder—Doxorubicin—liver cancer	0.00215	0.00256	CcSEcCtD
Darifenacin—Hyperhidrosis—Doxorubicin—liver cancer	0.00214	0.00255	CcSEcCtD
Darifenacin—Dyspnoea—Epirubicin—liver cancer	0.00213	0.00254	CcSEcCtD
Darifenacin—Somnolence—Epirubicin—liver cancer	0.00212	0.00254	CcSEcCtD
Darifenacin—Dyspepsia—Epirubicin—liver cancer	0.0021	0.00251	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Epirubicin—liver cancer	0.00206	0.00246	CcSEcCtD
Darifenacin—Constipation—Epirubicin—liver cancer	0.00204	0.00244	CcSEcCtD
Darifenacin—Pain—Epirubicin—liver cancer	0.00204	0.00244	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00201	0.00241	CcSEcCtD
Darifenacin—Insomnia—Doxorubicin—liver cancer	0.002	0.00239	CcSEcCtD
Darifenacin—Dyspnoea—Doxorubicin—liver cancer	0.00197	0.00235	CcSEcCtD
Darifenacin—Feeling abnormal—Epirubicin—liver cancer	0.00197	0.00235	CcSEcCtD
Darifenacin—Somnolence—Doxorubicin—liver cancer	0.00197	0.00235	CcSEcCtD
Darifenacin—Gastrointestinal pain—Epirubicin—liver cancer	0.00195	0.00233	CcSEcCtD
Darifenacin—Dyspepsia—Doxorubicin—liver cancer	0.00195	0.00232	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00191	0.00228	CcSEcCtD
Darifenacin—Constipation—Doxorubicin—liver cancer	0.00189	0.00226	CcSEcCtD
Darifenacin—Pain—Doxorubicin—liver cancer	0.00189	0.00226	CcSEcCtD
Darifenacin—Abdominal pain—Epirubicin—liver cancer	0.00189	0.00226	CcSEcCtD
Darifenacin—Feeling abnormal—Doxorubicin—liver cancer	0.00182	0.00218	CcSEcCtD
Darifenacin—Gastrointestinal pain—Doxorubicin—liver cancer	0.00181	0.00216	CcSEcCtD
Darifenacin—Hypersensitivity—Epirubicin—liver cancer	0.00176	0.0021	CcSEcCtD
Darifenacin—Abdominal pain—Doxorubicin—liver cancer	0.00175	0.00209	CcSEcCtD
Darifenacin—Asthenia—Epirubicin—liver cancer	0.00171	0.00205	CcSEcCtD
Darifenacin—Pruritus—Epirubicin—liver cancer	0.00169	0.00202	CcSEcCtD
Darifenacin—Diarrhoea—Epirubicin—liver cancer	0.00164	0.00195	CcSEcCtD
Darifenacin—Hypersensitivity—Doxorubicin—liver cancer	0.00163	0.00195	CcSEcCtD
Darifenacin—Asthenia—Doxorubicin—liver cancer	0.00159	0.00189	CcSEcCtD
Darifenacin—Dizziness—Epirubicin—liver cancer	0.00158	0.00189	CcSEcCtD
Darifenacin—Pruritus—Doxorubicin—liver cancer	0.00156	0.00187	CcSEcCtD
Darifenacin—Vomiting—Epirubicin—liver cancer	0.00152	0.00181	CcSEcCtD
Darifenacin—Diarrhoea—Doxorubicin—liver cancer	0.00151	0.00181	CcSEcCtD
Darifenacin—Rash—Epirubicin—liver cancer	0.00151	0.0018	CcSEcCtD
Darifenacin—Dermatitis—Epirubicin—liver cancer	0.00151	0.0018	CcSEcCtD
Darifenacin—Headache—Epirubicin—liver cancer	0.0015	0.00179	CcSEcCtD
Darifenacin—Dizziness—Doxorubicin—liver cancer	0.00146	0.00175	CcSEcCtD
Darifenacin—Nausea—Epirubicin—liver cancer	0.00142	0.00169	CcSEcCtD
Darifenacin—Vomiting—Doxorubicin—liver cancer	0.00141	0.00168	CcSEcCtD
Darifenacin—Rash—Doxorubicin—liver cancer	0.00139	0.00166	CcSEcCtD
Darifenacin—Dermatitis—Doxorubicin—liver cancer	0.00139	0.00166	CcSEcCtD
Darifenacin—Headache—Doxorubicin—liver cancer	0.00139	0.00165	CcSEcCtD
Darifenacin—Nausea—Doxorubicin—liver cancer	0.00131	0.00157	CcSEcCtD
Darifenacin—CYP3A4—Metabolism—GSTA4—liver cancer	5.57e-05	0.000343	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GOT2—liver cancer	5.49e-05	0.000338	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—BRAF—liver cancer	5.44e-05	0.000335	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTA2—liver cancer	5.43e-05	0.000334	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CSF2—liver cancer	5.43e-05	0.000334	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—RAF1—liver cancer	5.41e-05	0.000334	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CSF2—liver cancer	5.41e-05	0.000333	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—RAF1—liver cancer	5.4e-05	0.000332	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CSF2—liver cancer	5.36e-05	0.00033	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—H2AFX—liver cancer	5.35e-05	0.000329	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—IL2—liver cancer	5.35e-05	0.000329	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—RAF1—liver cancer	5.34e-05	0.000329	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—H2AFX—liver cancer	5.33e-05	0.000328	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—IL2—liver cancer	5.33e-05	0.000328	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3CD—liver cancer	5.31e-05	0.000327	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—PIK3CB—liver cancer	5.29e-05	0.000326	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—H2AFX—liver cancer	5.28e-05	0.000325	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—IL2—liver cancer	5.28e-05	0.000325	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—PIK3CB—liver cancer	5.27e-05	0.000325	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—PIK3CA—liver cancer	5.26e-05	0.000324	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—SERPINE1—liver cancer	5.26e-05	0.000324	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTA1—liver cancer	5.24e-05	0.000323	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—PIK3CB—liver cancer	5.22e-05	0.000321	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—KRAS—liver cancer	5.2e-05	0.00032	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NAT2—liver cancer	5.18e-05	0.000319	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP2E1—liver cancer	5.16e-05	0.000318	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CD—liver cancer	5.09e-05	0.000313	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—PIK3CA—liver cancer	5.04e-05	0.00031	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—SERPINE1—liver cancer	5.03e-05	0.00031	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—KRAS—liver cancer	4.98e-05	0.000307	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALDOB—liver cancer	4.96e-05	0.000306	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CG—liver cancer	4.86e-05	0.000299	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—IL2—liver cancer	4.85e-05	0.000299	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—IL2—liver cancer	4.84e-05	0.000298	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TERT—liver cancer	4.84e-05	0.000298	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYCS—liver cancer	4.83e-05	0.000298	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TERT—liver cancer	4.82e-05	0.000297	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—IL2—liver cancer	4.79e-05	0.000295	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—PIK3CA—liver cancer	4.78e-05	0.000294	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TERT—liver cancer	4.77e-05	0.000294	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—RAF1—liver cancer	4.74e-05	0.000292	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GOT1—liver cancer	4.74e-05	0.000292	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GGT1—liver cancer	4.74e-05	0.000292	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CRABP1—liver cancer	4.74e-05	0.000292	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PPARG—liver cancer	4.69e-05	0.000289	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3CB—liver cancer	4.63e-05	0.000285	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MTOR—liver cancer	4.63e-05	0.000285	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—PIK3CA—liver cancer	4.58e-05	0.000282	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—RAF1—liver cancer	4.54e-05	0.00028	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CB—liver cancer	4.43e-05	0.000273	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MTOR—liver cancer	4.43e-05	0.000273	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KDR—liver cancer	4.42e-05	0.000273	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—HRAS—liver cancer	4.42e-05	0.000272	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KDR—liver cancer	4.41e-05	0.000272	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAPK14—liver cancer	4.39e-05	0.000271	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAPK14—liver cancer	4.38e-05	0.00027	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KDR—liver cancer	4.37e-05	0.000269	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CDKN1B—liver cancer	4.35e-05	0.000268	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAPK14—liver cancer	4.34e-05	0.000267	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ESR1—liver cancer	4.31e-05	0.000266	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—AKT1—liver cancer	4.3e-05	0.000265	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ESR1—liver cancer	4.3e-05	0.000265	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CD—liver cancer	4.27e-05	0.000263	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CASP3—liver cancer	4.26e-05	0.000262	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—F2—liver cancer	4.26e-05	0.000262	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTP1—liver cancer	4.26e-05	0.000262	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ESR1—liver cancer	4.26e-05	0.000262	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL2—liver cancer	4.25e-05	0.000262	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—F2—liver cancer	4.24e-05	0.000262	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—HRAS—liver cancer	4.23e-05	0.000261	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—IL6—liver cancer	4.23e-05	0.000261	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ALB—liver cancer	4.22e-05	0.00026	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—F2—liver cancer	4.2e-05	0.000259	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—HMOX1—liver cancer	4.2e-05	0.000259	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CDKN1B—liver cancer	4.16e-05	0.000256	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCND1—liver cancer	4.15e-05	0.000255	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HPGDS—liver cancer	4.14e-05	0.000255	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—JUN—liver cancer	4.14e-05	0.000255	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—AKT1—liver cancer	4.12e-05	0.000254	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CTNNB1—liver cancer	4.11e-05	0.000253	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CASP3—liver cancer	4.08e-05	0.000251	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—APC—liver cancer	4.08e-05	0.000251	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CG—liver cancer	4.08e-05	0.000251	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL2—liver cancer	4.07e-05	0.000251	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—APC—liver cancer	4.06e-05	0.00025	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CG—liver cancer	4.06e-05	0.00025	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—IL6—liver cancer	4.05e-05	0.00025	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MMP9—liver cancer	4.03e-05	0.000248	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CG—liver cancer	4.02e-05	0.000248	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—APC—liver cancer	4.02e-05	0.000248	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CDKN1A—liver cancer	4.01e-05	0.000247	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCND1—liver cancer	3.97e-05	0.000245	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—JUN—liver cancer	3.96e-05	0.000244	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CTNNB1—liver cancer	3.93e-05	0.000242	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MAPK8—liver cancer	3.91e-05	0.000241	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTM1—liver cancer	3.91e-05	0.000241	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—AKT1—liver cancer	3.9e-05	0.000241	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MMP9—liver cancer	3.85e-05	0.000237	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CDKN1A—liver cancer	3.84e-05	0.000237	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—BRAF—liver cancer	3.83e-05	0.000236	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—BRAF—liver cancer	3.82e-05	0.000235	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—BRAF—liver cancer	3.78e-05	0.000233	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MAPK8—liver cancer	3.75e-05	0.000231	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—AKT1—liver cancer	3.74e-05	0.00023	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CB—liver cancer	3.72e-05	0.000229	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP1A1—liver cancer	3.71e-05	0.000228	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PSMD10—liver cancer	3.69e-05	0.000227	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PSMA4—liver cancer	3.69e-05	0.000227	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—VEGFA—liver cancer	3.61e-05	0.000223	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GOT2—liver cancer	3.59e-05	0.000221	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CD—liver cancer	3.58e-05	0.000221	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—STAT3—liver cancer	3.58e-05	0.00022	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CD—liver cancer	3.57e-05	0.00022	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—PIK3CA—liver cancer	3.55e-05	0.000219	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SERPINE1—liver cancer	3.54e-05	0.000218	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—PIK3CA—liver cancer	3.54e-05	0.000218	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CD—liver cancer	3.54e-05	0.000218	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SERPINE1—liver cancer	3.53e-05	0.000218	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—KRAS—liver cancer	3.51e-05	0.000216	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—PIK3CA—liver cancer	3.5e-05	0.000216	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SERPINE1—liver cancer	3.5e-05	0.000215	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—KRAS—liver cancer	3.5e-05	0.000215	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—KRAS—liver cancer	3.46e-05	0.000213	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—VEGFA—liver cancer	3.46e-05	0.000213	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—MTHFR—liver cancer	3.46e-05	0.000213	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—STAT3—liver cancer	3.43e-05	0.000211	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PPARA—liver cancer	3.39e-05	0.000209	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP2E1—liver cancer	3.37e-05	0.000208	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MYC—liver cancer	3.33e-05	0.000205	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TGFB1—liver cancer	3.32e-05	0.000204	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—PIK3CA—liver cancer	3.22e-05	0.000199	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—PIK3CA—liver cancer	3.21e-05	0.000198	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—RAF1—liver cancer	3.2e-05	0.000197	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—RAF1—liver cancer	3.19e-05	0.000196	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MYC—liver cancer	3.18e-05	0.000196	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—PIK3CA—liver cancer	3.18e-05	0.000196	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TGFB1—liver cancer	3.18e-05	0.000196	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYCS—liver cancer	3.16e-05	0.000195	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—RAF1—liver cancer	3.16e-05	0.000195	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CB—liver cancer	3.12e-05	0.000192	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MTOR—liver cancer	3.12e-05	0.000192	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MTOR—liver cancer	3.11e-05	0.000192	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CB—liver cancer	3.11e-05	0.000192	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GOT1—liver cancer	3.1e-05	0.000191	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GGT1—liver cancer	3.1e-05	0.000191	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MTOR—liver cancer	3.08e-05	0.00019	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CB—liver cancer	3.08e-05	0.00019	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—KRAS—liver cancer	3.07e-05	0.000189	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—HRAS—liver cancer	2.98e-05	0.000184	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—HRAS—liver cancer	2.97e-05	0.000183	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—HRAS—liver cancer	2.94e-05	0.000181	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—KRAS—liver cancer	2.94e-05	0.000181	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CDKN1B—liver cancer	2.93e-05	0.000181	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CDKN1B—liver cancer	2.92e-05	0.00018	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CG—liver cancer	2.9e-05	0.000179	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—AKT1—liver cancer	2.9e-05	0.000179	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CDKN1B—liver cancer	2.89e-05	0.000178	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—AKT1—liver cancer	2.89e-05	0.000178	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CASP3—liver cancer	2.87e-05	0.000177	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL2—liver cancer	2.87e-05	0.000177	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CASP3—liver cancer	2.86e-05	0.000176	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—AKT1—liver cancer	2.86e-05	0.000176	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL2—liver cancer	2.86e-05	0.000176	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—IL6—liver cancer	2.85e-05	0.000176	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—IL6—liver cancer	2.84e-05	0.000175	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CASP3—liver cancer	2.84e-05	0.000175	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL2—liver cancer	2.83e-05	0.000174	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3CA—liver cancer	2.82e-05	0.000174	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—IL6—liver cancer	2.82e-05	0.000174	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PPARG—liver cancer	2.8e-05	0.000173	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCND1—liver cancer	2.8e-05	0.000172	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—JUN—liver cancer	2.79e-05	0.000172	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCND1—liver cancer	2.79e-05	0.000172	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTP1—liver cancer	2.78e-05	0.000171	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—JUN—liver cancer	2.78e-05	0.000171	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CTNNB1—liver cancer	2.77e-05	0.000171	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CTNNB1—liver cancer	2.76e-05	0.00017	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCND1—liver cancer	2.76e-05	0.00017	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—JUN—liver cancer	2.75e-05	0.00017	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HMOX1—liver cancer	2.74e-05	0.000169	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CTNNB1—liver cancer	2.73e-05	0.000168	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TP53—liver cancer	2.73e-05	0.000168	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MMP9—liver cancer	2.71e-05	0.000167	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MMP9—liver cancer	2.71e-05	0.000167	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CDKN1A—liver cancer	2.7e-05	0.000167	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CA—liver cancer	2.7e-05	0.000167	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CDKN1A—liver cancer	2.7e-05	0.000166	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MMP9—liver cancer	2.68e-05	0.000165	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CDKN1A—liver cancer	2.67e-05	0.000164	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAPK8—liver cancer	2.64e-05	0.000163	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—AKT1—liver cancer	2.63e-05	0.000162	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAPK8—liver cancer	2.63e-05	0.000162	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—AKT1—liver cancer	2.62e-05	0.000162	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TP53—liver cancer	2.62e-05	0.000161	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—HRAS—liver cancer	2.61e-05	0.000161	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAPK8—liver cancer	2.61e-05	0.000161	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—AKT1—liver cancer	2.6e-05	0.00016	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTM1—liver cancer	2.56e-05	0.000158	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CD—liver cancer	2.55e-05	0.000157	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ALB—liver cancer	2.52e-05	0.000155	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—HRAS—liver cancer	2.5e-05	0.000154	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL6—liver cancer	2.5e-05	0.000154	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—VEGFA—liver cancer	2.44e-05	0.00015	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—VEGFA—liver cancer	2.43e-05	0.00015	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP1A1—liver cancer	2.42e-05	0.000149	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—STAT3—liver cancer	2.41e-05	0.000149	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—VEGFA—liver cancer	2.41e-05	0.000148	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—STAT3—liver cancer	2.41e-05	0.000148	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL6—liver cancer	2.39e-05	0.000147	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—STAT3—liver cancer	2.38e-05	0.000147	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—AKT1—liver cancer	2.31e-05	0.000142	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CA—liver cancer	2.27e-05	0.00014	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—MTHFR—liver cancer	2.26e-05	0.000139	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MYC—liver cancer	2.24e-05	0.000138	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TGFB1—liver cancer	2.24e-05	0.000138	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MYC—liver cancer	2.24e-05	0.000138	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TGFB1—liver cancer	2.23e-05	0.000137	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CB—liver cancer	2.23e-05	0.000137	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PPARA—liver cancer	2.22e-05	0.000137	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MYC—liver cancer	2.21e-05	0.000136	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—AKT1—liver cancer	2.21e-05	0.000136	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TGFB1—liver cancer	2.21e-05	0.000136	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KRAS—liver cancer	2.07e-05	0.000128	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KRAS—liver cancer	2.07e-05	0.000127	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KRAS—liver cancer	2.05e-05	0.000126	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CA—liver cancer	1.9e-05	0.000117	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CG—liver cancer	1.9e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CA—liver cancer	1.9e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CA—liver cancer	1.88e-05	0.000116	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AKT1—liver cancer	1.85e-05	0.000114	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TP53—liver cancer	1.84e-05	0.000113	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TP53—liver cancer	1.84e-05	0.000113	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PPARG—liver cancer	1.83e-05	0.000113	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TP53—liver cancer	1.82e-05	0.000112	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—HRAS—liver cancer	1.76e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HRAS—liver cancer	1.76e-05	0.000108	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HRAS—liver cancer	1.74e-05	0.000107	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL6—liver cancer	1.69e-05	0.000104	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL6—liver cancer	1.68e-05	0.000104	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CD—liver cancer	1.67e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL6—liver cancer	1.66e-05	0.000103	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALB—liver cancer	1.65e-05	0.000102	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AKT1—liver cancer	1.56e-05	9.58e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AKT1—liver cancer	1.55e-05	9.55e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AKT1—liver cancer	1.54e-05	9.46e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CB—liver cancer	1.46e-05	8.97e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CA—liver cancer	1.36e-05	8.36e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AKT1—liver cancer	1.11e-05	6.83e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CA—liver cancer	8.87e-06	5.47e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AKT1—liver cancer	7.25e-06	4.46e-05	CbGpPWpGaD
